Syntegra is a technology company.
Syntegra has raised $6.0M across 1 funding round.
Syntegra has raised $6.0M in total across 1 funding round.
Syntegra has raised $6.0M in total across 1 funding round.
Syntegra's investors include 01 Advisors, 20VC, Accomplice VC, Adverb Ventures, Chloe Sladden, Jana Messerschmidt, Bam Ventures, B Capital Group, Benchmark, Bessemer Venture Partners, Boston Seed Capital, C2 Investment.
Syntegra is a San Francisco-based healthcare technology company specializing in synthetic data generation to enable privacy-preserving access to realistic patient-level health data.[1][2][4] It builds the Syntegra Medical Mind, a machine learning model that converts real-world electronic medical records into synthetic data—statistically accurate but not linked to actual patients—solving the core problem of data privacy barriers that hinder innovation in healthcare research and development.[1][2][4] Syntegra serves a wide range of customers, including health systems, life sciences companies, health tech firms, payers, clinical research organizations, and data scientists, accelerating personalized medicine, drug development, and care delivery.[1][2][4] The company raised $5.625 million in seed funding led by Sweat Equity Ventures and Hike Ventures, signaling strong early growth momentum in the synthetic data space.[2]
Syntegra emerged to tackle the challenge of petabytes of electronic medical record data rendered unusable for research due to privacy regulations.[2][4] Founded in San Francisco (with headquarters listed in San Mateo, CA), the company leverages state-of-the-art machine learning to generate "realistic but not real" synthetic data, enabling easy sharing across stakeholders.[2] Key early milestones include a 2021 partnership with the Institute for Health Metrics for scalable data access and a 2022 collaboration with TMA Precision Health to speed rare disease diagnostics using synthetic data tools.[2] These moves built initial traction, positioning Syntegra as a pioneer in commercial synthetic healthcare data shortly after its seed funding.[2][4]
(Note: Specific founders are not detailed in available sources; the focus is on the team's expertise in machine learning and healthcare data.)
Syntegra stands out in the synthetic data market through these key strengths:
Syntegra rides the wave of AI-driven personalized medicine and the explosion of real-world evidence (RWE), where privacy laws like HIPAA block 99% of healthcare data's potential value.[1][4] Its timing aligns with surging demand for synthetic data amid AI advancements in transformers and multimodal models, enabling proactive, equitable healthcare over reactive models.[1] Market forces favoring Syntegra include regulatory pressures for data de-identification, the shift to value-based care, and digital health's need for fast, shareable data—fueling exponential innovation in drug discovery and care delivery.[2][4] By democratizing data access, Syntegra influences the ecosystem as a foundational enabler, empowering life sciences and health tech to iterate faster and improve patient outcomes at scale.[1][4]
Syntegra is poised to dominate synthetic healthcare data as AI models grow more sophisticated, with expansions like its API driving adoption across global health ecosystems.[4] Upcoming trends—such as multimodal data integration (e.g., genomics + imaging) and federated learning—will amplify its flywheel, potentially capturing a massive share of the $10B+ RWE market.[1][4] Its influence could evolve from niche innovator to infrastructure layer, enabling breakthroughs in rare diseases and precision medicine, provided it sustains data partnerships and model training. This positions Syntegra as a quiet game-changer, transforming privacy-protected data into the fuel for healthcare's AI revolution—directly advancing its mission to accelerate innovation for better patient care.[1][4]
Syntegra has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $6.0M Seed | 01 Advisors, 20VC, Accomplice VC, Adverb Ventures, Chloe Sladden, Jana Messerschmidt, Bam Ventures, B Capital Group, Benchmark, Bessemer Venture Partners, Boston Seed Capital, C2 Investment, Goat Capital, Impact VC, Menlo Ventures, Moxxie Ventures, NextGen Venture Partners, Polaris Partners, Techstars, Village Global, VitalStage Ventures, XStarPartners, Y Combinator, Aaron Levie, Adrian Aoun, David Cancel, David Chang, Elad Gil, Eric Wu, Jason Robins, Jennifer Lum, Joshua Reeves, Kevin Weil, Merlin Kauffman, Ric Fulop, Wayne Chang |